It's summertime, and the livin' is easy, but the Business of Biotech and Bioprocess Online have been hopping. We kicked off our July podcast lineup with some super innovative guests, including Claris Bio's Clarke Atwell, who's busy bringing topically-administered biologics to the front of the eye, Syncromune's Eamonn Hobbs, whose experience constitutes a masterclass in navigating the complexity of biologic drug/device combination therapies, and Aulos Bioscience CEO Aron Knickerbocker, who holds the unique distinction of putting the first AI-designed antibody into humans. Catch up on all the latest episodes here.
On this month's Bioprocess Online Live, I dug into the ADC burgeon among small biotechs with Mythic Therapeutics COO Sandra Poole, Vincerx Pharma CMO Amy Johnson, Ph.D, and DeciBio ADC expert Joe Daccache, Ph.D. Watch that on-demand here.
From July 22 to 24, I'll be in D.C., hanging with the single-use elite at the Bioprocess Systems Alliance's annual conference. Let me know if you're in town.
On the supplier front, we're bringing you a jam-packed, three-day, virtual and interactive display of the latest upstream, downstream, and quality/analytical solutions with BioExpo Live July 30 through August 1. Register (free) for one or more of those sessions here.
Phew! I just got back from a beach vacation, and I already feel like I need another.
Keep it dialed on the Business of Biotech and Bioprocess Online to make sure you don't miss anything. Meanwhile, here's a roundup of my top picks from the Life Science Connect community's raging river of biopharma business content. Grab a cold one and enjoy!
Matt Pillar, Business of Biotech host and chief editor, Bioprocess Online |
|
| | Biotech Beat | July 23, 2024 |
|
| ![]() | | by MATT PILLAR | My pal Anna Rose Welch leans hard into pop culture analogies in much of the content she writes over at Advancing RNA. I'm not as good at it, but I gave it a go in this commentary on the wild progress we're seeing on the ADC landscape. It might have taken a hundred years, but a combination of tech advances and sheer grit are combining to pay BIG ADC dividends. | READ NOW → |
|
![]() | | by BEN COMER | What could accelerate your clinical development program faster than unfettered access to a trove of historical clinical data from peer companies in your oncology space? The CEO Rountable On Cancer is a who's-who of biopharma CEOs working with the largest privately-held software company in the world to make it happen safely, legally, and ethically. Life Science Leader's Ben Comer caught up with the project's lead man here. | READ NOW → |
|
| ![]() | | by LOUIS GARGUILO | Over at Outsourced Pharma, our Louis Garguillo has been diligently giving readers a blow-by-blow account of the Biosecure Act saga, with a focus on its implications for WuXi. The biotech leaders I've recently spoken with in the ADC space, in particular, have been gnashing teeth and wringing hands over it. Looks like they can rest easy — for now. But, as Louis states in this article, while the Act has been tabled, the fallout remains. | READ NOW → |
|
![]() | | by ANNA ROSE WELCH | Speaking of Anna Rose Welch, she's been cranking out a series of hot takes on mRNA development. Since COVID, it's been too easy to watch this space through rose-colored glasses, but in these assessments, she's not pulling any punches. This one was published in June, so it's a good place to start dialing into Anna Rose's perspectives, which just keep coming. | READ NOW → |
|
| | "We got a big pharma partnership for an ophthalmology program that continues to advance and it looks incredibly exciting, but we're not ophthalmology experts. We're cell transplant experts. So the point is scale." | ― Brian Culley, CEO, Lineage Cell Therapeutics, Episode 207 |
|
| "Every VC that you talk to, their first thought is, how do I just get rid of this? And if they can't come up with a reason, then they start to get interested and they move forward." | ― Clarke Atwell, Founding CEO, Claris Bio, Episode 208 |
|
| "Most biotech companies fail because the hypothesis failed, and that's with brilliant minds that have M.D.s, Ph.D.s, making phenomenally good decisions that turned out to not be correct." | ― Eamonn Hobbs, President & CEO, Syncromune, Episode 209 |
|
| | | ![]() | Created exclusively for the leaders of new and emerging biopharma firms, the Business of Biotech podcast tackles organizational, funding, HR, regulatory, production and CMC considerations with insight from peer founders who have taken biologic therapies from an idea to clinical success. Check out our episode archive. | |
|
|
|
Ensure our newsletter reaches your inbox by following these whitelist instructions.
This newsletter is being sent to {{lead.Email Address}}. To cancel your subscription to the newsletter, please opt out. | © Copyright 2024 Vertmarkets, Inc. 5340 Fryling Rd Suite 100, Erie, PA 16510.
All rights reserved. All product names contained herein are the trademarks of their respective holders. |
|
|
|
|
